Use of mutational profiling of metastatic ER+/HER2- breast cancers and the coexistence of KRAS, MET, BRAF, and FGFR3 with PIK3CA mutations.
Debora Fumagalli
No relevant relationships to disclose
Roberto Salgado
No relevant relationships to disclose
Carmen Criscitiello
No relevant relationships to disclose
Lina Pugliano
No relevant relationships to disclose
Ioanna Laios
No relevant relationships to disclose
Timothy Wilson
Employment or Leadership Position - Genentech/Roche
Denis Larsimont
No relevant relationships to disclose
Martine J. Piccart-Gebhart
No relevant relationships to disclose
Stefan Michiels
No relevant relationships to disclose
Mark Lackner
Employment or Leadership Position - Genentech/Roche
Christos Sotiriou
No relevant relationships to disclose
Sherene Loi
No relevant relationships to disclose